FS Reports最新文献

{"title":"Incidental seminoma in nonobstructive azoospermia: a case report","authors":"Jonathan Gal MD ,&nbsp;Juan Miguel Mosquera MD, MSc ,&nbsp;Brian D. Robinson MD ,&nbsp;Peter N. Schlegel MD","doi":"10.1016/j.xfre.2024.04.001","DOIUrl":"10.1016/j.xfre.2024.04.001","url":null,"abstract":"<div><h3>Objective</h3><p>To report on the incidental finding of invasive seminoma in a patient with nonobstructive azoospermia during microdissection testicular sperm extraction.</p></div><div><h3>Design</h3><p>Case report.</p></div><div><h3>Patient(s)</h3><p>A single patient diagnosed with nonobstructive azoospermia underwent microdissection testicular sperm extraction, and an incidental finding of invasive seminoma was made upon histopathological analysis.</p></div><div><h3>Result(s)</h3><p>An incidental discovery of invasive seminoma was observed in the sample pathology obtained during the microdissection testicular sperm extraction. Consequently, the patient underwent further diagnostic workup and a radical orchiectomy.</p></div><div><h3>Conclusion(s)</h3><p>Men with male factor infertility are at increased risk of testicular cancer. As such, it is imperative to incorporate a thorough physical examination and relevant imaging into their diagnostic process. Additionally, it is advisable to include histopathological analysis for all individuals undergoing microdissection testicular sperm extraction.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 211-213"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000485/pdfft?md5=1c47ef400ea1362d86e8401c0d17230f&pid=1-s2.0-S2666334124000485-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluoroscopic-guided hysteroscopic tubal cannulation results in high technical success and pregnancy rates comparable with the more traditional laparoscopically guided hysteroscopic tubal cannulation","authors":"Martin Keltz M.D. ,&nbsp;Sarah C. Rubin B.S. ,&nbsp;Emma Brown B.A. ,&nbsp;Moses Bibi B.S. ,&nbsp;May-Tal Sauerbrun-Cutler M.D.","doi":"10.1016/j.xfre.2024.02.008","DOIUrl":"10.1016/j.xfre.2024.02.008","url":null,"abstract":"<div><h3>Objective</h3><p>To compare women with proximal tubal obstruction (PTO) undergoing hysteroscopic tubal cannulation with fluoroscopic guidance vs. laparoscopic guidance.</p></div><div><h3>Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting</h3><p>All fluoroscopically-guided hysteroscopic tubal cannulations were performed in an ambulatory suite. All laparoscopically-guided hysteroscopic tubal cannulations were performed in a hospital operating room.</p></div><div><h3>Patients</h3><p>Infertile women with unilateral or bilateral PTO on hysterosalpingography who failed selective salpingography in the radiology suite and had a planned laparoscopy or hysteroscopy in the operating room for defects seen on sonohysterography were studied.</p></div><div><h3>Intervention</h3><p>All women had a Novy catheter system positioned hysteroscopically to cannulate the occluded fallopian tube(s). Women undergoing fluoroscopically guided hysteroscopic tubal cannulation (FHTC), which used contrast and C-arm pelvic imaging at an ambulatory center, were compared with those undergoing hospital-based laparoscopically guided hysteroscopic tubal cannulation (LHTC) with laparoscopic visualization.</p></div><div><h3>Main Outcome Measurements</h3><p>Tubal cannulation success; bilateral cannulation success; tubal perforations; post-FHTC non–in vitro fertilization (non-IVF) intrauterine pregnancies; days from procedure to pregnancy for non-IVF intrauterine pregnancies; and time to non-IVF pregnancy hazards ratio.</p></div><div><h3>Results</h3><p>A total of 76 infertile women undergoing either FHTC (34 women) or LHTC (42 women) between 2015 and 2019 were included. Demographic variables were similar among the 2 groups. A total of 31 (92%) of 34 of patients undergoing FHTC and 36 (86%) of 42 of patients undergoing LHTC had at least one tube successfully cannulated. In total, 30 (78%) of 34 of patients undergoing FHTC and 32 (79%) of 42 patients undergoing LHTC had all occluded tubes successfully cannulated. Tubal perforation occurred in 1 (3%) of 34 FHTC cases and 3 (7%) of 42 LHTC cases. A similar percentage of non-IVF treatment-induced intrauterine pregnancies were achieved in the FHTC and LHTC groups (10/34 [29%] vs. 12/42 [29%]). Among patients who conceived without IVF, time from procedure to pregnancy was lower in the FHTC group (101 ± 124.6 days) compared with the LHTC group (228 ± 216 days). There was a significant difference in time to pregnancy when only those who conceived were considered (hazard ratio, 9.39; 95% confidence interval, 2.42–36.51); however, there was no significant difference when all subjects regardless of pregnancy outcome were analyzed (hazard ratio, 1.48; 95% confidence interval, 0.64–3.446).</p></div><div><h3>Conclusion</h3><p>Fluoroscopically guided hysteroscopic tubal cannulation is a safe, effective, incision free procedure that results in comparable rates of tubal patency and intrauterine pregnancies as LHTC. This technique ","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 205-210"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266633412400014X/pdfft?md5=c5098f975af56506a1b7dc2cb4c10493&pid=1-s2.0-S266633412400014X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139967192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous ovarian stimulation: a proof-of-concept study exploring the uninterrupted use of corifollitropin α in DuoStim cycles for enhanced efficiency and patient convenience (Alicante protocol)","authors":"Juan Carlos Castillo M.D., Ph.D. ,&nbsp;Ana Fuentes M.D. ,&nbsp;Jose Antonio Ortiz M.Sc., Ph.D. ,&nbsp;Esther Abellán M.Sc. ,&nbsp;Andrea Bernabeu M.D., Ph.D. ,&nbsp;Rafael Bernabeu M.D., Ph.D.","doi":"10.1016/j.xfre.2024.03.005","DOIUrl":"10.1016/j.xfre.2024.03.005","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the use of weekly continuous dosing of corifollitropin α in DuoStim cycles.</p></div><div><h3>Design</h3><p>Pilot-matched case-control study.</p></div><div><h3>Setting</h3><p>Private fertility center.</p></div><div><h3>Patient(s)</h3><p>Cases were defined as DuoStim cycles performed from November 2022 to May 2023 receiving weekly continuous dosing of corifollitropin α (n = 15). Controls were chosen from a database comprising DuoStim cycles conducted at our institution during the years 2021/2022. Matching was done on a 1-to-1 basis, based on antimüllerian hormone values (±0.4 pmol/L) and age (n = 15).</p></div><div><h3>Intervention(s)</h3><p>Injections of corifollitropin α once every 8 days, along with uninterrupted oral administration of micronized progesterone 200 mg/d (for luteinizing hormone surge prevention) throughout the follicular and luteal phases for ovarian stimulation. Oocyte retrieval.</p></div><div><h3>Main outcome measure(s)</h3><p>Total number of cumulus-oocyte complexes and metaphase II oocytes obtained in follicular + luteal phase stimulation. Secondary outcomes evaluated fertilization rates, number of blastocysts, days of stimulation, number of injectables required, and gonadotropin cost.</p></div><div><h3>Result(s)</h3><p>The study group achieved similar total oocyte and MII yield vs. daily follicle-stimulating hormone protocol (13.3 ± 6.9 vs. 11.8 ± 6.1 and 10.4 ± 6.3 vs. 9.2 ± 4.6, respectively). All secondary outcomes showed no significant differences. The study group experienced a significant reduction of injections to complete a DuoStim cycle (4.5 ± 1.4 vs. 35.2 ± 12.2; mean deviation -30.7; 95% confidence interval, −37.5– to −23.9)].</p></div><div><h3>Conclusion(s)</h3><p>Corifollitropin α on a weekly basis throughout a DuoStim cycle yields an equivalent number of oocytes as standard daily follicle-stimulating hormone administration while drastically reducing the number of required injections.</p></div><div><h3>Trial registration number</h3><p>NCT05815719. EudraCT: 2022-003177-32.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 176-182"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000461/pdfft?md5=d3eeaf7fd8d09fd64e65748138c7478a&pid=1-s2.0-S2666334124000461-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uterus transplantation: a rescue technique to save the viability and functionality of the graft after intra-operative outflow thrombosis","authors":"Giuseppe D'Amico M.D. ,&nbsp;Koji Hashimoto M.D. ,&nbsp;Luca Del Prete M.D. ,&nbsp;Elliott Richards M.D. ,&nbsp;Stephanie Ricci M.D. ,&nbsp;Rebecca Flyck M.D. ,&nbsp;Bijan Eghtesad M.D. ,&nbsp;Teresa Diago M.D. ,&nbsp;Tommaso Falcone M.D. ,&nbsp;Charles Miller M.D. ,&nbsp;Andreas Tzakis M.D. ,&nbsp;Cristiano Quintini M.D.","doi":"10.1016/j.xfre.2024.02.002","DOIUrl":"10.1016/j.xfre.2024.02.002","url":null,"abstract":"<div><h3>Objective</h3><p>To study a surgical approach to venous vascular thrombosis after uterus transplantation (UTx). Uterus transplantation is the only treatment for uterine factor infertility when conventional therapies are not possible. One of the major limitations of UTx is the high incidence of vascular thrombosis, which in most series reaches approximately 20%.</p></div><div><h3>Design</h3><p>A case report.</p></div><div><h3>Setting</h3><p>Hospital.</p></div><div><h3>Patients</h3><p>We report here a technique used in a 30-year-old woman with congenital absence of the uterus who developed intraoperative thrombosis after a UTx from a brain-dead donor.</p></div><div><h3>Intervention</h3><p>The UTx was performed by revascularizing the graft through bilateral donor internal iliac vessels (artery and vein) anastomosed end-to-side to the external iliac vessels of the recipient. The superior uterine veins were not anastomosed and were left unreconstructed. An end-to-end graft to the recipient’s vaginal anastomosis was performed. After uterus reperfusion, congestion of the organ was noted, and bilateral venous thrombosis of the internal iliac veins of the graft was found. A “Y-shaped” venous jump graft was used to restore venous outflow of the left superior uterine vein and the internal iliac vein of the graft after thrombectomy.</p></div><div><h3>Main Outcome Measures</h3><p>Viability and functionality of the uterus graft after intraoperative bilateral venous thrombosis.</p></div><div><h3>Results</h3><p>The postoperative course was uneventful, and this UTx resulted in the delivery of a healthy infant.</p></div><div><h3>Conclusion</h3><p>To our knowledge, this is the first successful rescue technique used to restore venous outflow and save the viability and functionality of a transplanted uterus. We demonstrated that a transplanted uterus from a deceased donor with a monolateral outflow could succeed in pregnancy and the delivery of a healthy infant.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 223-227"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000084/pdfft?md5=b69583cd2f9d103cc1707674ebe27afc&pid=1-s2.0-S2666334124000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to Family Building Act: an antidote to Alabama’s Supreme Court Holding on in vitro fertilization","authors":"Eli Y. Adashi M.D., M.S. ,&nbsp;Daniel P. O’Mahony M.S.L.S.","doi":"10.1016/j.xfre.2024.03.001","DOIUrl":"10.1016/j.xfre.2024.03.001","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 128-129"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000424/pdfft?md5=f88b6e22ef121b3e10a0d5baf55a0e7e&pid=1-s2.0-S2666334124000424-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140282714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel antimüllerian gene mutation in a woman with high antral follicle count and extremely low serum antimüllerian hormone levels","authors":"Laura Melado M.D., Ph.D. ,&nbsp;Barbara Lawrenz M.D., Ph.D. ,&nbsp;Jonalyn Edades B.S. ,&nbsp;Ajay Kumar Ph.D. ,&nbsp;Human Fatemi M.D., Ph.D.","doi":"10.1016/j.xfre.2024.01.006","DOIUrl":"10.1016/j.xfre.2024.01.006","url":null,"abstract":"<div><h3>Objective</h3><p>To report a case with a distinct difference between the ovarian reserve parameters of antimüllerian hormone (AMH) levels, antral follicle count (AFC), and follicle-stimulating hormone levels caused by a novel homozygous missense variant in the exon 1 of the <em>AMH</em> gene [NM_000479.4:c259G&gt;A, p.(Val87Met)].</p></div><div><h3>Design</h3><p>Case report.</p></div><div><h3>Setting</h3><p>Tertiary referral in vitro fertilization clinic.</p></div><div><h3>Patients</h3><p>A 33-year-old woman, G4P4A0E0L4, with a BMI of 25.33 kg/m², high AFC, and repeated extremely low systemic AMH levels, was detected and measured using multiple enzyme-linked immunosorbent assays.</p></div><div><h3>Interventions</h3><p>Antimüllerian hormone analysis with multiple assays, whole exome sequencing through next generation sequencing to diagnose the missense variant, and inhibin B measurement.</p></div><div><h3>Main Outcomes Measures</h3><p>Genetic counseling and two subsequent ovarian stimulations for successful fertility preservation.</p></div><div><h3>Results</h3><p>Detection of the [NM_000479.4:c259G&gt;A, p.(Val87Met)] variant in the AMH gene. Retrieval and cryopreservation of four euploid blastocysts and 26 metaphase II oocytes.</p></div><div><h3>Conclusions</h3><p><em>AMH</em> gene mutations can lead to the absence of systemic AMH levels and might be discordant to other ovarian reserve markers like AFC, follicle-stimulating hormone, and inhibin B, without affecting the ovarian response to ovarian stimulation. Clinicians should not rely exclusively on AMH levels for ovarian stimulation. When severely reduced AMH levels are found in patients with high AFC, AMH variants should be suspected, and fertility treatments should be tailored adequately.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 152-156"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000060/pdfft?md5=042c6db73bc685da15f064acae9fa346&pid=1-s2.0-S2666334124000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitrification: pursuing technologies to improve safety and efficacy","authors":"Richard T. Scott Jr. M.D., H.C.L.D./A.L.D.","doi":"10.1016/j.xfre.2024.02.006","DOIUrl":"10.1016/j.xfre.2024.02.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 134-135"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000126/pdfft?md5=fa4b2d5c9e2ec54c98bcae2bb5ad3da1&pid=1-s2.0-S2666334124000126-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of letrozole regimens for ovulation induction in women with polycystic ovary syndrome","authors":"Rachel S. Mandelbaum M.D. ,&nbsp;Ravi Agarwal M.D. ,&nbsp;Samuel Melville M.D. ,&nbsp;Caroline J. Violette M.D. ,&nbsp;Sharon Winer M.D. ,&nbsp;Donna Shoupe M.D. ,&nbsp;Koji Matsuo M.D., Ph.D. ,&nbsp;Richard J. Paulson M.D. ,&nbsp;Molly M. Quinn M.D.","doi":"10.1016/j.xfre.2024.03.004","DOIUrl":"10.1016/j.xfre.2024.03.004","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the optimal letrozole regimen for ovulation induction (OI) in women with polycystic ovary syndrome (PCOS)</p></div><div><h3>Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting</h3><p>Single academic fertility clinic from 2015–2022.</p></div><div><h3>Patient(s)</h3><p>A total of 189 OI cycles in 52 patients with PCOS</p></div><div><h3>Intervention(s)</h3><p>Patients were prescribed 1 of 4 letrozole regimens (group 1: 2.5 mg for 5 days, group 2: 2.5 mg for 10 days, group 3: 5 mg for 5 days, and group 4: 5 mg for 10 days).</p></div><div><h3>Main outcome measure(s)</h3><p>The primary outcome was ovulation, and secondary outcomes included multifollicular development, and clinical pregnancy rate, which were analyzed with binary logistic regression. Kaplan-Meier cumulative response curves and a Cox proportional hazard regression model were used for time-dependent analyses.</p></div><div><h3>Results</h3><p>Mean age was 30.9 years (standard deviation [SD], 3.6) and body mass index was 32.1 kg/m² (SD, 4.0). Group 2 (odds ratio [OR], 9.12; 95% confidence interval [CI], 1.92–43.25), group 3 (OR, 3.40; 95% CI, 1.57-7.37), and group 4 (OR, 5.94; 95% CI, 2.48–14.23) had improved ovulation rates after the starting regimen as compared with group 1. Cumulative ovulation rates exceeded 84% in all groups, yet those who received 5 mg and/or 10 days achieved ovulation significantly sooner. Multifollicular development was not increased in groups 2–4 as compared with group 1. Groups 2–4 also demonstrated improved time to pregnancy.</p></div><div><h3>Conclusions</h3><p>Ovulation rates are improved when starting with letrozole at 5 mg and/or a 10-day extended course as compared with the frequently-used 2.5 mg for 5 days. This may shorten time to ovulation and pregnancy.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 170-175"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266633412400045X/pdfft?md5=1e60d051cbd494954a160f964cb35283&pid=1-s2.0-S266633412400045X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three live births after human embryo vitrification with the use of aluminum oxide as an intermediate cooling agent: a case report","authors":"Plamen Todorov D.Sc. ,&nbsp;Elena Hristova Ph.D. ,&nbsp;Nadya Petrova Ph.D. ,&nbsp;Tanya Milachich Ph.D.","doi":"10.1016/j.xfre.2024.01.003","DOIUrl":"10.1016/j.xfre.2024.01.003","url":null,"abstract":"<div><h3>Objective</h3><p>To study the possibility of increasing the cooling rates of the vitrification procedure in a closed system with the use of aluminum oxide as an intermediate coolant.</p></div><div><h3>Design</h3><p>Case report.</p></div><div><h3>Subjects</h3><p>Six patients undergoing procedures for assisted reproduction.</p></div><div><h3>Intervention</h3><p>Comparative studies of cryopreservation of donor embryos with aluminum oxide as an intermediate cooling agent (experimental group) and without it (control group) have been performed. After thawing, the embryo morphology and its potential to develop to the blastocyst stage have been assessed. The methodology was then applied to clinical practice.</p></div><div><h3>Main Outcome Measures</h3><p>Twenty embryos of 6 patients have been vitrified on day 4 after fertilization with the use of aluminum oxide as an intermediate coolant. Fourteen of them have been thawed. All have displayed normal morphology and 10 have formed blastocysts after 24 hours of culture. Four of the patients received embryo transfer with 2 embryos and the other 2 with single embryos.</p></div><div><h3>Results</h3><p>After preliminary comparative studies of embryos frozen with aluminum oxide and a control group, the results showed no statistically significant difference between their quality and potential to reach to blastocyst stage. That gave us ground to apply the methodology in clinical practice. After the embryo transfer, 3 clinical pregnancies with successful live births have been obtained.</p></div><div><h3>Conclusions</h3><p>Our experience shows that preimplantation embryos can be cryopreserved aseptically, in closed systems, with the help of aluminum oxide as an intermediate coolant.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 145-151"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000035/pdfft?md5=f9d412dff87474b25cfcb036f49dba49&pid=1-s2.0-S2666334124000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139537282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management guidelines for incidental uterine surgery in early pregnancy: a case report of a robotic myomectomy at 4 weeks gestation after a false-negative pregnancy test","authors":"Abaigeal Thompson M.D. ,&nbsp;Melanie Evans M.D. ,&nbsp;Patrick Weix M.D., Ph.D.","doi":"10.1016/j.xfre.2024.04.002","DOIUrl":"10.1016/j.xfre.2024.04.002","url":null,"abstract":"<div><h3>Objective</h3><p>To share our case and offer guidance to practitioners on the management of incidental uterine surgery in early pregnancy. Although elective uterine surgery should be avoided during pregnancy, there is always a chance of undetected pregnancy at the time of surgery, even after all precautions have been taken. There is currently minimal literature on the management and outcomes of uterine surgery during pregnancy.</p></div><div><h3>Design</h3><p>Case report.</p></div><div><h3>Setting</h3><p>University Hospital.</p></div><div><h3>Patient</h3><p>A 42-year-old G1P1 female with symptomatic fibroids desiring fertility-sparing surgery was retroactively found to be 4 weeks pregnant at the time of surgery, even after a negative pregnancy test and low suspicion for pregnancy under Centers for Disease Control and Prevention guidelines.</p></div><div><h3>Intervention</h3><p>Robotic-assisted laparoscopic myomectomy performed with a false-negative urine pregnancy test at the time of surgery.</p></div><div><h3>Main Outcome Measures</h3><p>Guidance for surveillance and management options during continued pregnancy after robotic uterine surgery and cavity disruption by a uterine manipulator performed at 4 weeks gestation that went undetected at the time of surgery.</p></div><div><h3>Results</h3><p>The patient was able to undergo an uncomplicated delivery by cesarean section at 38 weeks and delivered a healthy infant.</p></div><div><h3>Conclusion</h3><p>Using a multidisciplinary approach, we describe guidelines for antepartum surveillance uterine surgery during an undetected pregnancy, which resulted in the delivery of a term healthy infant.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 219-222"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000497/pdfft?md5=dfe7874beb049e96a961a564294e901e&pid=1-s2.0-S2666334124000497-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140789997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}